Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus EPINASTINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus EPINASTINE HYDROCHLORIDE.
ACUVUE THERAVISION WITH KETOTIFEN vs EPINASTINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Selective histamine H1-receptor antagonist. Inhibits histamine release from mast cells and basophils, and reduces chemotaxis and activation of eosinophils. Also suppresses cytokine production from T lymphocytes.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
For allergic rhinitis and urticaria: 10 mg twice daily orally (20 mg/day). For ophthalmic use: 1 drop in affected eye(s) twice daily of 0.05% solution.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
The terminal elimination half-life is approximately 5.7 to 9.2 hours in healthy adults. In elderly patients, the half-life may be prolonged due to reduced renal function. The half-life supports twice-daily dosing for most indications.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal excretion accounts for approximately 39% of the administered dose, with about 28% as unchanged drug and 11% as metabolites. Fecal excretion is minimal at approximately 10%. Biliary excretion is not a significant route. Overall, renal clearance is the primary elimination pathway.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine